

NCT02763007 Raw comparison:

Summary:
CHIA has 13 criteria while your personal folder has 15 criteria
Total found criteria: 13/13
Total not Found: 0/13
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Completed "ALO-IIT-012(PEAK study)" without major  │ Completed "ALO-IIT-012(PEAK study)" without major  │
│ protocol deviations                                │ protocol deviations                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Male or female 19 years to 75 years                │ Male or female 19 years to 75 years                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female with childbearing potential who has a       │ Female with childbearing potential who has a       │
│ negative urine pregnancy test result at study      │ negative urine pregnancy test result at study      │
│ start and willing to continue practice appropriate │ start and willing to continue practice appropriate │
│ birth control during the entire duration of study  │ birth control during the entire duration of study  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects completed PEAK can be included within 30  │ Subjects completed PEAK can be included within 30  │
│ days after End Of the Study                        │ days after End Of the Study                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects completed PEAK can be included if their   │ Subjects completed PEAK can be included if their   │
│ treatment is the same as randomized even after 30  │ treatment is the same as randomized even after 30  │
│ days of End Of the Study                           │ days of End Of the Study                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ eGFR(Epidermal growth factor receptor) < 50mL/min  │ eGFR(Epidermal growth factor receptor) \< 50mL/min │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ AST(aspartate aminotransferase)/ALT(alanine        │ AST(aspartate aminotransferase)/ALT(alanine        │
│ aminotransaminase) >2 5 upper limit of normal      │ aminotransaminase) \>2 5 upper limit of normal     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or lactating women                        │ Pregnant or lactating women                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject who the investigator deems inappropriate   │ Subject who the investigator deems inappropriate   │
│ to participate in this study                       │ to participate in this study                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with a history of bladder cancer or       │ Patients with a history of bladder cancer or       │
│ patients with active bladder cancer                │ patients with active bladder cancer                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with uninvestigated macroscopic hematuria │ Patients with uninvestigated macroscopic hematuria │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with cardiac failure or a history of      │ Patients with cardiac failure or a history of      │
│ cardiac failure (New York Heart Association [NYHA] │ cardiac failure (New York Heart Association        │
│ Stages 3 to 4)                                     │ \[NYHA\] Stages 3 to 4)                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with genetic problems such as galactose   │ Patients with genetic problems such as galactose   │
│ intolerance Lapp lactase deficiency or glucose-    │ intolerance Lapp lactase deficiency or glucose-    │
│ galactose malabsorption since this study drug      │ galactose malabsorption since this study drug      │
│ contains lactose                                   │ contains lactose                                   │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have maximum age of 75 Years │
├───────────────────────────────────┤
│ Must have minimum age of 19 Years │
╘═══════════════════════════════════╛